All 1 tracked stories fall under one category: pharma. Korlym is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Corcept Therapeutics Incorporated, all published on February 24, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Corcept Therapeutics Incorporated
All 1 tracked stories fall under one category: pharma. Korlym is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Corcept Therapeutics Incorporated, all published on February 24, 2026. Each carries 10 original sources on average.
Stories tracked
1
Sources per story
10
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Corcept Therapeutics Incorporated. Shared-story counts are live from our verified record — not editorial picks.
Rosen Law Firm has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT), alleging securities fraud during a period of intense patent litigation over its flagship drug, Korlym. The lawsuit covers investors who purchased shares between October 2024 and December 2025, following significant volatility linked to generic competition threats.
Corcept Therapeutics Incorporated is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.